Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02316444
Other study ID # U010
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date November 2015
Est. completion date April 28, 2017

Study information

Verified date January 2019
Source Fred Hutchinson Cancer Research Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to compare the effectiveness of two vaccination strategies against Hepatitis B virus (HBV) in subjects already infected with human immunodeficiency virus (HIV).

Researchers plan to determine the optimal vaccination strategy for achieving protective immunity to HBV infection in HIV-infected adults attending Mulago Hospital's HIV care clinic.

Primary objectives are to assess:

1. The role of CD4-cell count and HIV viral loads on the HBV vaccine response.

2. The role of highly active antiretroviral therapy (HAART) on the HBV vaccine response.

The secondary objective is to evaluate whether lack of HAART is associated with high rates of loss to follow-up.


Description:

This is an interventional study in which researchers will recruit HIV positive individuals who do not have hepatitis B (HBV negative) in order to assess the effectiveness of a hepatitis B vaccine in 2 subgroups:

1. Those who have received less than 3 months treatment, or no treatment, with highly active antiretroviral drugs (HAART naive).

2. Those who have received at least 3 months of treatment with highly active antiretroviral drugs (HAART exposed).

All study participants will receive vaccination against HBV.

There will be 6-12 clinic visits depending on 1) whether or not the participant responds to the standard 3-dose vaccination protocol and 2) whether he or she suffers a clinical condition or vaccine related adverse event that would call for postponement of the next vaccine dose.

The first visit will be to determine if the participant is eligible for the study. If eligible, the participant will receive one dose of vaccine at each of the following three visits. The fifth visit will be to collect blood to determine whether the participant has responded to the 3-dose vaccination protocol. The sixth visit will be to discuss the outcome of the vaccination with the participant. Participants who respond favorably to the 3-dose vaccine protocol will exit the study at this point. However, if a participant fails to respond to the initial 3-dose vaccine protocol, he or she may restart the regimen and receive another 3 doses of vaccine following the same schedule as before but off protocol.

Participants will be reimbursed for travel costs to and from the clinic for scheduled clinic visits.


Recruitment information / eligibility

Status Completed
Enrollment 132
Est. completion date April 28, 2017
Est. primary completion date April 28, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Hepatitis B core antibody (anti-HBc) and anti-HBs negative

2. Age =18 years

3. HIV infected persons (HAART naïve and HAART exposed). HAART enrollees will be considered to be HAART exposed if they have been taking these medications for at least 3 months. Participants that have never been on HAART and those that have been on HAART for <3months will be considered to be HAART naïve. HAART exposed enrollees will have an adherence of at least 95%.

4. Ambulatory

5. Intention to attend the Mulago HIV/AIDS clinic for the 18 months

6. Able and willing to comply with study protocol including providing informed consent

Exclusion Criteria:

1. History of hypersensitivity to vaccines or intolerance to any of the HBV vaccine components

2. Previously-confirmed diagnosis of decompensated liver disease or HCC

3. Serological evidence of prior receipt of the HBV vaccine (anti-HBS positive, anti-HBc negative) or documented (clinical) evidence of having been vaccinated.

4. Known history of HBV infection (HBsAg and/or anti-HBc positive).

5. Inability to follow study procedures

6. If a participant chooses not to consent to the review of his or her medical records

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Hepatitis B vaccine
An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses off protocol

Locations

Country Name City State
Uganda Mulago National referral hospital Kampala

Sponsors (3)

Lead Sponsor Collaborator
Fred Hutchinson Cancer Research Center Makerere University, Uganda Cancer Institute

Country where clinical trial is conducted

Uganda, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hepatitis B virus (HBV) vaccine response Measure Hepatitis B surface antibody (anti-HBs) levels and cell mediated immune response. 18 months
Secondary Loss to follow-up (HAART naive vs. HAART exposed individuals) Compare the number of individuals lost to follow-up among the HAART naive and HAART exposed. 18 months
See also
  Status Clinical Trial Phase
Completed NCT03063385 - Puerto Rico Cuidalos Parent-adolescent Program N/A
Active, not recruiting NCT04283929 - Evaluation of Clinical Impacts and Costs of eHealth in Rwanda N/A
Withdrawn NCT03938077 - A Community-University Approach to Preventing HIV N/A
Recruiting NCT04319367 - A Randomised Placebo Controlled Trial of ART Plus Dual Long-acting HIV-specific Broadly Neutralising Antibodies (bNAbs). Phase 2
Completed NCT03368456 - Preventing HIV/STI in Urban Adolescents Via an mHealth Primary Care Intervention N/A
Recruiting NCT04135443 - Evaluation of 3T, a Sex-Positive HIV/STI Mobile App Intervention for Young Black Men Ages 14-19 Attracted to Men N/A
Completed NCT03404297 - Compression Therapy for Leg Ulcers and Kaposi Sarcoma in Western Kenya N/A
Completed NCT03198663 - POSSE Project: A Community-Level Intervention for Black YMSM N/A
Completed NCT03445351 - Quality of Life, Sleep, and Biomarkers in People With HIV/AIDS N/A
Completed NCT03252483 - Integrating HIV and Hepatitis C Screening in an Urban Emergency Department N/A
Completed NCT02712801 - Antiretroviral Regime for Viral Eradication in Newborns Phase 4
Completed NCT02406482 - Evaluating a Microfinance Intervention for Vulnerable Women in Kazakhstan N/A
Recruiting NCT04788784 - Patient-Reported Outcomes HIV BItherapy
Recruiting NCT05300035 - Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control Phase 2